Estimating infection fatality risk and ascertainment bias of COVID-19 in Osaka, Japan from February 2020 to January 2022
The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from February 2020 to January 2022. We used two types of datasets: (i) surveillance-based datasets containing the cumulative numbers of confirmed cases and death...
Saved in:
| Published in | Scientific reports Vol. 13; no. 1; pp. 5540 - 9 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
04.04.2023
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from February 2020 to January 2022. We used two types of datasets: (i) surveillance-based datasets containing the cumulative numbers of confirmed cases and deaths in each epidemic wave and (ii) seroepidemiological datasets conducted in a serial cross-sectional manner. Smoothing spline function was employed to reconstruct the age-specific cumulative incidence of infection. We found that IFR was highest during the first wave, and the second highest during the fourth wave, caused by the Alpha variant. Once vaccination became widespread, IFR decreased considerably among adults aged 40 years plus during the fifth wave caused by the Delta variant, although the epidemic size of fifth wave was the largest before the Omicron variant emerged. We also found that ascertainment bias was relatively high during the first and second waves and, notably, RT-PCR testing capacity during these early periods was limited. Improvements in the ascertainment were seen during the third and fourth waves. Once the Omicron variant began spreading, IFR diminished while ascertainment bias was considerably elevated. |
|---|---|
| AbstractList | The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from February 2020 to January 2022. We used two types of datasets: (i) surveillance-based datasets containing the cumulative numbers of confirmed cases and deaths in each epidemic wave and (ii) seroepidemiological datasets conducted in a serial cross-sectional manner. Smoothing spline function was employed to reconstruct the age-specific cumulative incidence of infection. We found that IFR was highest during the first wave, and the second highest during the fourth wave, caused by the Alpha variant. Once vaccination became widespread, IFR decreased considerably among adults aged 40 years plus during the fifth wave caused by the Delta variant, although the epidemic size of fifth wave was the largest before the Omicron variant emerged. We also found that ascertainment bias was relatively high during the first and second waves and, notably, RT-PCR testing capacity during these early periods was limited. Improvements in the ascertainment were seen during the third and fourth waves. Once the Omicron variant began spreading, IFR diminished while ascertainment bias was considerably elevated. The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from February 2020 to January 2022. We used two types of datasets: (i) surveillance-based datasets containing the cumulative numbers of confirmed cases and deaths in each epidemic wave and (ii) seroepidemiological datasets conducted in a serial cross-sectional manner. Smoothing spline function was employed to reconstruct the age-specific cumulative incidence of infection. We found that IFR was highest during the first wave, and the second highest during the fourth wave, caused by the Alpha variant. Once vaccination became widespread, IFR decreased considerably among adults aged 40 years plus during the fifth wave caused by the Delta variant, although the epidemic size of fifth wave was the largest before the Omicron variant emerged. We also found that ascertainment bias was relatively high during the first and second waves and, notably, RT-PCR testing capacity during these early periods was limited. Improvements in the ascertainment were seen during the third and fourth waves. Once the Omicron variant began spreading, IFR diminished while ascertainment bias was considerably elevated. The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from February 2020 to January 2022. We used two types of datasets: (i) surveillance-based datasets containing the cumulative numbers of confirmed cases and deaths in each epidemic wave and (ii) seroepidemiological datasets conducted in a serial cross-sectional manner. Smoothing spline function was employed to reconstruct the age-specific cumulative incidence of infection. We found that IFR was highest during the first wave, and the second highest during the fourth wave, caused by the Alpha variant. Once vaccination became widespread, IFR decreased considerably among adults aged 40 years plus during the fifth wave caused by the Delta variant, although the epidemic size of fifth wave was the largest before the Omicron variant emerged. We also found that ascertainment bias was relatively high during the first and second waves and, notably, RT-PCR testing capacity during these early periods was limited. Improvements in the ascertainment were seen during the third and fourth waves. Once the Omicron variant began spreading, IFR diminished while ascertainment bias was considerably elevated.The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from February 2020 to January 2022. We used two types of datasets: (i) surveillance-based datasets containing the cumulative numbers of confirmed cases and deaths in each epidemic wave and (ii) seroepidemiological datasets conducted in a serial cross-sectional manner. Smoothing spline function was employed to reconstruct the age-specific cumulative incidence of infection. We found that IFR was highest during the first wave, and the second highest during the fourth wave, caused by the Alpha variant. Once vaccination became widespread, IFR decreased considerably among adults aged 40 years plus during the fifth wave caused by the Delta variant, although the epidemic size of fifth wave was the largest before the Omicron variant emerged. We also found that ascertainment bias was relatively high during the first and second waves and, notably, RT-PCR testing capacity during these early periods was limited. Improvements in the ascertainment were seen during the third and fourth waves. Once the Omicron variant began spreading, IFR diminished while ascertainment bias was considerably elevated. Abstract The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from February 2020 to January 2022. We used two types of datasets: (i) surveillance-based datasets containing the cumulative numbers of confirmed cases and deaths in each epidemic wave and (ii) seroepidemiological datasets conducted in a serial cross-sectional manner. Smoothing spline function was employed to reconstruct the age-specific cumulative incidence of infection. We found that IFR was highest during the first wave, and the second highest during the fourth wave, caused by the Alpha variant. Once vaccination became widespread, IFR decreased considerably among adults aged 40 years plus during the fifth wave caused by the Delta variant, although the epidemic size of fifth wave was the largest before the Omicron variant emerged. We also found that ascertainment bias was relatively high during the first and second waves and, notably, RT-PCR testing capacity during these early periods was limited. Improvements in the ascertainment were seen during the third and fourth waves. Once the Omicron variant began spreading, IFR diminished while ascertainment bias was considerably elevated. |
| ArticleNumber | 5540 |
| Author | Nishiura, Hiroshi Zhang, Tong |
| Author_xml | – sequence: 1 givenname: Tong surname: Zhang fullname: Zhang, Tong organization: School of Public Health, Kyoto University – sequence: 2 givenname: Hiroshi surname: Nishiura fullname: Nishiura, Hiroshi email: nishiura.hiroshi.5r@kyoto-u.ac.jp organization: School of Public Health, Kyoto University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37016060$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuEzEUHaEiWkp_gAWyxIYFA36MZ8YrVIUWgiplA2ytOx47OJ3YwXYQ_Xtumra0XdQb29fnnPvweVkdhBhsVb1m9AOjov-YGyZVX1MuasFboWr1rDritJE1F5wf3DsfVic5ryguyVXD1IvqUHSUtbSlR9Xfs1z8GooPS-KDs6b4GIiDApMvVyT5fEkgjASysamAD2sbChk8ZBIdmS1-zj_XTCGVLDJcwnvyDTaAAimuybkd0hbSFeGUU1IivoXbO39VPXcwZXtysx9XP87Pvs--1heLL_PZ6UVtWtqV2tl25MoZGAyKjE51XLUO--06y6Vh4zi6XlrGukGKceBWtoMywimMdX0ziONqvtcdI6z0JmGz6UpH8Po6ENNSQyreTFYb3inJhegxVzMyqwY2dGAG4KbHVA61Pu21NtthbUeDo0gwPRB9-BL8L72MfzSjtONUUFR4d6OQ4u-tzUWvPU52miDYuM0aK2iZ7BvZI_TtI-gqblPAWe1QkqoGYYh6c7-ku1pufxgBfA8wKeacrLuDMKp3TtJ7J2l0kr52klZI6h-RjC-wswa25aenqWJPzZgnLG36X_YTrH-1CttY |
| CitedBy_id | crossref_primary_10_1016_j_jvacx_2024_100547 crossref_primary_10_1038_s41598_024_57238_0 crossref_primary_10_1186_s44263_024_00069_y crossref_primary_10_1007_s11538_024_01298_w crossref_primary_10_1093_ofid_ofae685 |
| Cites_doi | 10.2188/jea.JE20210324 10.1038/s41541-021-00396-3 10.1016/S0140-6736(21)02867-1 10.54034/mic.e1256 10.1016/j.puhe.2021.11.023 10.1007/s10654-020-00698-1 10.1038/s41467-020-19509-y 10.1155/2018/3407306 10.1001/jamanetworkopen.2021.37257 10.3390/jcm9020419 10.3201/eid2702.204088 10.1016/S0140-6736(22)00484-6 10.1016/S0140-6736(22)00462-7 10.1093/aje/kws314 10.1016/S0140-6736(22)00172-6 10.1136/bmj.m4509 10.31662/jmaj.2020-0094 10.1002/rmv.2162 10.1038/s41586-020-2918-0 10.2471/BLT.20.265892 10.1128/Spectrum.00341-21 10.2807/1560-7917.ES.2020.25.12.2000256 10.1016/S1473-3099(20)30769-6 10.1038/s43856-022-00106-7 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-023-32639-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_c27952338bc04d1e9b1b7acba2c85c1f PMC10072030 37016060 10_1038_s41598_023_32639_9 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Japan Osaka Japan |
| GeographicLocations_xml | – name: Japan – name: Osaka Japan |
| GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development grantid: JP20fk0108140; JP20fk0108535; JP21fk0108612 funderid: http://dx.doi.org/10.13039/100009619 – fundername: Strategic International Collaborative Research Program grantid: JPMJSC20U3; JPMJSC2105 funderid: http://dx.doi.org/10.13039/501100009036 – fundername: Japan Society for the Promotion of Science grantid: 21H03198 funderid: http://dx.doi.org/10.13039/501100001691 – fundername: Ministry of Health, Labour and Welfare grantid: 20CA2024; 20HA2007; 21HB1002; 21HA2016 funderid: http://dx.doi.org/10.13039/501100003478 – fundername: ; grantid: JP20fk0108140; JP20fk0108535; JP21fk0108612 – fundername: ; grantid: JPMJSC20U3; JPMJSC2105 – fundername: ; grantid: 20CA2024; 20HA2007; 21HB1002; 21HA2016 – fundername: ; grantid: 21H03198 |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK AARCD COVID K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c607t-fe6d29fcabc020df97296f63977e25c1dddf85e117b53db2e56b9c3f95e1784b3 |
| IEDL.DBID | M48 |
| ISSN | 2045-2322 |
| IngestDate | Wed Aug 27 01:31:41 EDT 2025 Thu Aug 21 18:38:51 EDT 2025 Fri Jul 11 05:55:12 EDT 2025 Wed Aug 13 05:11:33 EDT 2025 Thu Jan 02 22:52:15 EST 2025 Tue Jul 01 04:24:27 EDT 2025 Thu Apr 24 22:55:18 EDT 2025 Fri Feb 21 02:37:18 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-fe6d29fcabc020df97296f63977e25c1dddf85e117b53db2e56b9c3f95e1784b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-023-32639-9 |
| PMID | 37016060 |
| PQID | 2795094845 |
| PQPubID | 2041939 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c27952338bc04d1e9b1b7acba2c85c1f pubmedcentral_primary_oai_pubmedcentral_nih_gov_10072030 proquest_miscellaneous_2796158458 proquest_journals_2795094845 pubmed_primary_37016060 crossref_primary_10_1038_s41598_023_32639_9 crossref_citationtrail_10_1038_s41598_023_32639_9 springer_journals_10_1038_s41598_023_32639_9 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-04 |
| PublicationDateYYYYMMDD | 2023-04-04 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | NybergTComparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort studyLancet2022399130313121:CAS:528:DC%2BB38XnslSjsrw%3D10.1016/S0140-6736(22)00462-7353052968926413 Osaka Prefectural Government. Incidence of New Coronavirus Infection. https://www.pref.osaka.lg.jp/iryo/osakakansensho/happyo.html (Accessed 20 April 2022). YoshiyamaTPrevalence of SARS-CoV-2-specific antibodies, Japan, June 2020Emerg. Infect. Dis.2021276286311:CAS:528:DC%2BB3MXhtVKqurzO10.3201/eid2702.204088334962357853542 Japan Broadcasting Corporation. Graph of First Wave to Seventh Epidemic Wave. https://www3.nhk.or.jp/news/special/coronavirus/entire/ (Accessed 25 July 2022). O'DriscollMAge-specific mortality and immunity patterns of SARS-CoV-2Nature20215901401452021Natur.590..140O1:CAS:528:DC%2BB3cXisFCgtLvI10.1038/s41586-020-2918-033137809 National Institute of Infectious Diseases. Seroepidemiological Study on New Coronavirus Infection in 2021. https://www.niid.go.jp/niid/images/epi/corona/79/covid19-79.pdf (Accessed 15 April 2022). LevinATAssessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implicationsEur. J. Epidemiol.202035112311381:CAS:528:DC%2BB3cXis1ShtrrK10.1007/s10654-020-00698-1332899007721859 BollykyTJPandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021Lancet20223991489151210.1016/S0140-6736(22)00172-6 Ministry of Health, Labour and Welfare. List of Information for Local Governments and Medical Institutions (Contact) (New Model Coronavirus Infection) 2020. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00212.html (Accessed 20 May 2022). Prime Minister’s Office of Japan. New Corona Vaccine. https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html (Accessed 10 April 2022). IoannidisJPAInfection fatality rate of COVID-19 inferred from seroprevalence dataBull. World Health Organ.2021991910.2471/BLT.20.26589233716331 Pecho-SilvaSSARS-CoV-2 mutations and variants: What do we know so far?Microbes Infect. Chemother.20211125610.54034/mic.e1256 WheelerSEDifferential antibody response to mRNA COVID-19 vaccines in healthy subjectsMicrobiol. Spectr.20219e003412110.1128/Spectrum.00341-2134346750 Pastor-BarriusoRInfection fatality risk for SARS-CoV-2 in community dwelling population of Spain: Nationwide seroepidemiological studyBMJ2020371m450910.1136/bmj.m450933246972 National Institute of Infectious Diseases. Coronavirus Disease (COVID-19). https://www.niid.go.jp/niid/en/ (Accessed 25 April 2022). Imperial College London. Real-Time Assessment of Community Transmission (REACT) Study. https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/real-time-assessment-of-community-transmission-findings/ (Accessed 15 July 2022). WongJYInfection fatality risk of the pandemic A(H1N1)2009 virus in Hong KongAm. J. Epidemiol.201317783484010.1093/aje/kws314234599503658096 NomuraSExcess deaths from COVID-19 in Japan and 47 prefectures from January through June 2021Public Health202220315181:STN:280:DC%2BB2M%2FmvVemsA%3D%3D10.1016/j.puhe.2021.11.02335016070 FurukawaKSeroepidemiological survey of the antibody for severe acute respiratory syndrome coronavirus 2 with neutralizing activity at hospitals: A cross-sectional study in Hyogo Prefecture, JapanJMA J.20214414910.31662/jmaj.2020-0094335755027872787 BrazeauNFEstimating the COVID-19 infection fatality ratio accounting for seroreversion using statistical modellingCommun. Med.202225410.1038/s43856-022-00106-7356032709120146 NishiuraHThe rate of underascertainment of novel coronavirus (2019-nCoV) infection: Estimation using Japanese passengers data on evacuation flightsJ. Clin. Med.2020902041910.3390/jcm9020419 MaQGlobal percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysisJAMA Netw. Open20214e213725710.1001/jamanetworkopen.2021.37257349050088672238 SorensenRJDVariation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: A systematic analysisLancet2022399146914881:CAS:528:DC%2BB38Xls12ms7w%3D10.1016/S0140-6736(21)02867-1 AssisRDistinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccinationNPJ Vaccines202161321:CAS:528:DC%2BB3MXisVGksrbJ10.1038/s41541-021-00396-3347373188568980 BarberRMIEstimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: A statistical analysisLancet2021399235110.1016/S0140-6736(22)00484-6 Ministry of Health, Labour and Welfare. Fifth Council of Ministers on the Progress of New Coronavirus Infection Control. https://www.kantei.go.jp/jp/singi/novel_coronavirus/taisaku_shinchoku/dai5/siryou.pdf (Accessed 20 May 2022). Japanese Society for Infectious Diseases. Covid-19 Vaccine Recommendations (4th Edition). https://www.kansensho.or.jp/uploads/files/guidelines/2112_covid-19_4.pdf (Accessed 20 April 2022). SanadaTSerologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020–2021J. Epidemiol.20223210511110.2188/jea.JE20210324347764998761565 StreeckHInfection fatality rate of SARS-CoV2 in a super-spreading event in GermanyNat. Commun.20201158292020NatCo..11.5829S1:CAS:528:DC%2BB3cXitl2ns73J10.1038/s41467-020-19509-y332038877672059 Osaka Prefectural Government. Estimated Population of Osaka Prefecture Every Month. https://www.pref.osaka.lg.jp/toukei/jinkou/jinkou-xlslist.html (Accessed 10 May 2022). CsigeIThe impact of obesity on the cardiovascular systemJ. Diabetes Res.2018201834073061:CAS:528:DC%2BC1MXitVCjtr3K10.1155/2018/3407306305250526247580 World Health Organization. Weekly Epidemiological Update on COVID-19—25 January 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-january-2023 (Accessed 28 January 2023). YangWEstimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: A model-based analysisLancet Infect. Dis.2021212032121:CAS:528:DC%2BB3cXitFyqtLnF10.1016/S1473-3099(20)30769-633091374 MurchuEOImmune response following infection with SARS-CoV-2 and other coronaviruses: A rapid reviewRev. Med. Virol.202131e21621:CAS:528:DC%2BB3MXnt1aqu70%3D10.1002/rmv.2162 European Centre for Disease Prevention and Control. Variants of Concern. https://www.ecdc.europa.eu/en/covid-19/variants-concern (Accessed 20 June 2022). RussellTWEstimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020Eurosurveillance20202520025610.2807/1560-7917.ES.2020.25.12.2000256 Osaka Medical Center. Summary of Infection and Medical Conditions from First Wave to Fifth Wave. https://www.pref.osaka.lg.jp/attach/38215/00410045/1-2_1~5kansen1021.pdf (Accessed 25 May 2022). 32639_CR4 32639_CR2 Q Ma (32639_CR6) 2021; 4 32639_CR19 S Nomura (32639_CR29) 2022; 203 I Csige (32639_CR30) 2018; 2018 32639_CR1 H Nishiura (32639_CR18) 2020; 9 T Sanada (32639_CR34) 2022; 32 JPA Ioannidis (32639_CR12) 2021; 99 32639_CR5 T Nyberg (32639_CR26) 2022; 399 32639_CR35 EO Murchu (32639_CR37) 2021; 31 TW Russell (32639_CR9) 2020; 25 K Furukawa (32639_CR33) 2021; 4 SE Wheeler (32639_CR20) 2021; 9 AT Levin (32639_CR22) 2020; 35 32639_CR36 T Yoshiyama (32639_CR32) 2021; 27 32639_CR31 H Streeck (32639_CR13) 2020; 11 TJ Bollyky (32639_CR16) 2022; 399 S Pecho-Silva (32639_CR3) 2021; 1 R Pastor-Barriuso (32639_CR10) 2020; 371 RMI Barber (32639_CR7) 2021; 399 NF Brazeau (32639_CR17) 2022; 2 32639_CR24 32639_CR23 M O'Driscoll (32639_CR14) 2021; 590 32639_CR28 32639_CR27 32639_CR25 W Yang (32639_CR11) 2021; 21 JY Wong (32639_CR8) 2013; 177 RJD Sorensen (32639_CR15) 2022; 399 R Assis (32639_CR21) 2021; 6 |
| References_xml | – reference: Pecho-SilvaSSARS-CoV-2 mutations and variants: What do we know so far?Microbes Infect. Chemother.20211125610.54034/mic.e1256 – reference: Osaka Prefectural Government. Estimated Population of Osaka Prefecture Every Month. https://www.pref.osaka.lg.jp/toukei/jinkou/jinkou-xlslist.html (Accessed 10 May 2022). – reference: YangWEstimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: A model-based analysisLancet Infect. Dis.2021212032121:CAS:528:DC%2BB3cXitFyqtLnF10.1016/S1473-3099(20)30769-633091374 – reference: Imperial College London. Real-Time Assessment of Community Transmission (REACT) Study. https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/real-time-assessment-of-community-transmission-findings/ (Accessed 15 July 2022). – reference: National Institute of Infectious Diseases. Seroepidemiological Study on New Coronavirus Infection in 2021. https://www.niid.go.jp/niid/images/epi/corona/79/covid19-79.pdf (Accessed 15 April 2022). – reference: BarberRMIEstimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: A statistical analysisLancet2021399235110.1016/S0140-6736(22)00484-6 – reference: O'DriscollMAge-specific mortality and immunity patterns of SARS-CoV-2Nature20215901401452021Natur.590..140O1:CAS:528:DC%2BB3cXisFCgtLvI10.1038/s41586-020-2918-033137809 – reference: Osaka Medical Center. Summary of Infection and Medical Conditions from First Wave to Fifth Wave. https://www.pref.osaka.lg.jp/attach/38215/00410045/1-2_1~5kansen1021.pdf (Accessed 25 May 2022). – reference: StreeckHInfection fatality rate of SARS-CoV2 in a super-spreading event in GermanyNat. Commun.20201158292020NatCo..11.5829S1:CAS:528:DC%2BB3cXitl2ns73J10.1038/s41467-020-19509-y332038877672059 – reference: SorensenRJDVariation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: A systematic analysisLancet2022399146914881:CAS:528:DC%2BB38Xls12ms7w%3D10.1016/S0140-6736(21)02867-1 – reference: NishiuraHThe rate of underascertainment of novel coronavirus (2019-nCoV) infection: Estimation using Japanese passengers data on evacuation flightsJ. Clin. Med.2020902041910.3390/jcm9020419 – reference: AssisRDistinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccinationNPJ Vaccines202161321:CAS:528:DC%2BB3MXisVGksrbJ10.1038/s41541-021-00396-3347373188568980 – reference: LevinATAssessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implicationsEur. J. Epidemiol.202035112311381:CAS:528:DC%2BB3cXis1ShtrrK10.1007/s10654-020-00698-1332899007721859 – reference: CsigeIThe impact of obesity on the cardiovascular systemJ. Diabetes Res.2018201834073061:CAS:528:DC%2BC1MXitVCjtr3K10.1155/2018/3407306305250526247580 – reference: National Institute of Infectious Diseases. Coronavirus Disease (COVID-19). https://www.niid.go.jp/niid/en/ (Accessed 25 April 2022). – reference: MurchuEOImmune response following infection with SARS-CoV-2 and other coronaviruses: A rapid reviewRev. Med. Virol.202131e21621:CAS:528:DC%2BB3MXnt1aqu70%3D10.1002/rmv.2162 – reference: SanadaTSerologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020–2021J. Epidemiol.20223210511110.2188/jea.JE20210324347764998761565 – reference: RussellTWEstimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020Eurosurveillance20202520025610.2807/1560-7917.ES.2020.25.12.2000256 – reference: WongJYInfection fatality risk of the pandemic A(H1N1)2009 virus in Hong KongAm. J. Epidemiol.201317783484010.1093/aje/kws314234599503658096 – reference: WheelerSEDifferential antibody response to mRNA COVID-19 vaccines in healthy subjectsMicrobiol. Spectr.20219e003412110.1128/Spectrum.00341-2134346750 – reference: Japanese Society for Infectious Diseases. Covid-19 Vaccine Recommendations (4th Edition). https://www.kansensho.or.jp/uploads/files/guidelines/2112_covid-19_4.pdf (Accessed 20 April 2022). – reference: Osaka Prefectural Government. Incidence of New Coronavirus Infection. https://www.pref.osaka.lg.jp/iryo/osakakansensho/happyo.html (Accessed 20 April 2022). – reference: Japan Broadcasting Corporation. Graph of First Wave to Seventh Epidemic Wave. https://www3.nhk.or.jp/news/special/coronavirus/entire/ (Accessed 25 July 2022). – reference: FurukawaKSeroepidemiological survey of the antibody for severe acute respiratory syndrome coronavirus 2 with neutralizing activity at hospitals: A cross-sectional study in Hyogo Prefecture, JapanJMA J.20214414910.31662/jmaj.2020-0094335755027872787 – reference: BollykyTJPandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021Lancet20223991489151210.1016/S0140-6736(22)00172-6 – reference: Ministry of Health, Labour and Welfare. Fifth Council of Ministers on the Progress of New Coronavirus Infection Control. https://www.kantei.go.jp/jp/singi/novel_coronavirus/taisaku_shinchoku/dai5/siryou.pdf (Accessed 20 May 2022). – reference: Ministry of Health, Labour and Welfare. List of Information for Local Governments and Medical Institutions (Contact) (New Model Coronavirus Infection) 2020. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00212.html (Accessed 20 May 2022). – reference: MaQGlobal percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysisJAMA Netw. Open20214e213725710.1001/jamanetworkopen.2021.37257349050088672238 – reference: World Health Organization. Weekly Epidemiological Update on COVID-19—25 January 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-january-2023 (Accessed 28 January 2023). – reference: NomuraSExcess deaths from COVID-19 in Japan and 47 prefectures from January through June 2021Public Health202220315181:STN:280:DC%2BB2M%2FmvVemsA%3D%3D10.1016/j.puhe.2021.11.02335016070 – reference: NybergTComparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort studyLancet2022399130313121:CAS:528:DC%2BB38XnslSjsrw%3D10.1016/S0140-6736(22)00462-7353052968926413 – reference: IoannidisJPAInfection fatality rate of COVID-19 inferred from seroprevalence dataBull. World Health Organ.2021991910.2471/BLT.20.26589233716331 – reference: Pastor-BarriusoRInfection fatality risk for SARS-CoV-2 in community dwelling population of Spain: Nationwide seroepidemiological studyBMJ2020371m450910.1136/bmj.m450933246972 – reference: Prime Minister’s Office of Japan. New Corona Vaccine. https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html (Accessed 10 April 2022). – reference: BrazeauNFEstimating the COVID-19 infection fatality ratio accounting for seroreversion using statistical modellingCommun. Med.202225410.1038/s43856-022-00106-7356032709120146 – reference: European Centre for Disease Prevention and Control. Variants of Concern. https://www.ecdc.europa.eu/en/covid-19/variants-concern (Accessed 20 June 2022). – reference: YoshiyamaTPrevalence of SARS-CoV-2-specific antibodies, Japan, June 2020Emerg. Infect. Dis.2021276286311:CAS:528:DC%2BB3MXhtVKqurzO10.3201/eid2702.204088334962357853542 – ident: 32639_CR1 – volume: 32 start-page: 105 year: 2022 ident: 32639_CR34 publication-title: J. Epidemiol. doi: 10.2188/jea.JE20210324 – ident: 32639_CR19 – ident: 32639_CR5 – volume: 6 start-page: 132 year: 2021 ident: 32639_CR21 publication-title: NPJ Vaccines doi: 10.1038/s41541-021-00396-3 – ident: 32639_CR23 – volume: 399 start-page: 1469 year: 2022 ident: 32639_CR15 publication-title: Lancet doi: 10.1016/S0140-6736(21)02867-1 – ident: 32639_CR25 – volume: 1 start-page: 1256 year: 2021 ident: 32639_CR3 publication-title: Microbes Infect. Chemother. doi: 10.54034/mic.e1256 – volume: 203 start-page: 15 year: 2022 ident: 32639_CR29 publication-title: Public Health doi: 10.1016/j.puhe.2021.11.023 – volume: 35 start-page: 1123 year: 2020 ident: 32639_CR22 publication-title: Eur. J. Epidemiol. doi: 10.1007/s10654-020-00698-1 – ident: 32639_CR27 – volume: 11 start-page: 5829 year: 2020 ident: 32639_CR13 publication-title: Nat. Commun. doi: 10.1038/s41467-020-19509-y – volume: 2018 start-page: 3407306 year: 2018 ident: 32639_CR30 publication-title: J. Diabetes Res. doi: 10.1155/2018/3407306 – volume: 4 start-page: e2137257 year: 2021 ident: 32639_CR6 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2021.37257 – ident: 32639_CR36 – volume: 9 start-page: 020419 year: 2020 ident: 32639_CR18 publication-title: J. Clin. Med. doi: 10.3390/jcm9020419 – volume: 27 start-page: 628 year: 2021 ident: 32639_CR32 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2702.204088 – volume: 399 start-page: 2351 year: 2021 ident: 32639_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(22)00484-6 – volume: 399 start-page: 1303 year: 2022 ident: 32639_CR26 publication-title: Lancet doi: 10.1016/S0140-6736(22)00462-7 – volume: 177 start-page: 834 year: 2013 ident: 32639_CR8 publication-title: Am. J. Epidemiol. doi: 10.1093/aje/kws314 – volume: 399 start-page: 1489 year: 2022 ident: 32639_CR16 publication-title: Lancet doi: 10.1016/S0140-6736(22)00172-6 – volume: 371 start-page: m4509 year: 2020 ident: 32639_CR10 publication-title: BMJ doi: 10.1136/bmj.m4509 – volume: 4 start-page: 41 year: 2021 ident: 32639_CR33 publication-title: JMA J. doi: 10.31662/jmaj.2020-0094 – volume: 31 start-page: e2162 year: 2021 ident: 32639_CR37 publication-title: Rev. Med. Virol. doi: 10.1002/rmv.2162 – ident: 32639_CR2 – volume: 590 start-page: 140 year: 2021 ident: 32639_CR14 publication-title: Nature doi: 10.1038/s41586-020-2918-0 – ident: 32639_CR4 – ident: 32639_CR24 – volume: 99 start-page: 19 year: 2021 ident: 32639_CR12 publication-title: Bull. World Health Organ. doi: 10.2471/BLT.20.265892 – ident: 32639_CR28 – volume: 9 start-page: e0034121 year: 2021 ident: 32639_CR20 publication-title: Microbiol. Spectr. doi: 10.1128/Spectrum.00341-21 – volume: 25 start-page: 200256 year: 2020 ident: 32639_CR9 publication-title: Eurosurveillance doi: 10.2807/1560-7917.ES.2020.25.12.2000256 – ident: 32639_CR31 – volume: 21 start-page: 203 year: 2021 ident: 32639_CR11 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30769-6 – ident: 32639_CR35 – volume: 2 start-page: 54 year: 2022 ident: 32639_CR17 publication-title: Commun. Med. doi: 10.1038/s43856-022-00106-7 |
| SSID | ssj0000529419 |
| Score | 2.4288175 |
| Snippet | The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from February 2020... Abstract The present study aimed to estimate the infection fatality risk (IFR) and ascertainment bias of SARS-CoV-2 for six epidemic waves in Japan from... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 5540 |
| SubjectTerms | 631/114 692/308/174 692/700 692/700/459 692/700/478 Adult COVID-19 COVID-19 - epidemiology Cross-Sectional Studies Datasets Epidemics Fatalities Health risks Humanities and Social Sciences Humans Infections Japan - epidemiology multidisciplinary SARS-CoV-2 Science Science (multidisciplinary) Seroepidemiology Severe acute respiratory syndrome coronavirus 2 Vaccination |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwELZQJSQuiJ1AWxmJG7Ua23FiH-nyVHqgF4p6s7xCRXFQ8yrRf8_YSV77WC8cE9vRaBbPN_F4BqHXQnIaIegizAkIUGQbiWmtJ8FIz5SVtrYlQfZ9e3TaHJ-Js1utvnJO2FgeeGTcrmOdgmCJS-vqxtOgLLWdcdYwJ4WjMe--4PNuBVNjVW-mGqqmWzI1l7sDeKp8m4xxAoiFK6LWPFEp2P87lPlrsuRPJ6bFES0eoPsTgsRvR8ofojshPUJ3x56S14_R90Mw2gxD0yc8Z1olHPNfGgDcOKeSY5M8NoO7yQbA9twMuI94_-TjuwNCFSzFJ4P5YnbwMbhT-MBl_xUvIIAGlbrGDOAfXvYwluZn9gSdLg4_7B-Rqb0CcW3dLUkMLYgjOgOcZbWPCnB2G_NBXxcYsNZ7H6UIlHZWcG9ZEK1VjkcF7zrZWP4UbaQ-hecIR9gHGgjsbGxZExSVMQqAYs54bjtAoBWiM6u1m2qP5xYYF7qcgXOpR_FoEI8u4tGqQm9Wa76NlTf-OnsvS3A1M1fNLi9Al_SkS_pfulShzVn-ejLlQec1EAPLRlTo1WoYjDCfrJgU-qsyB5AhTJEVejaqy4oS3uUifm1dIbmmSGukro-k88-l0HfOYGGwC1doZ9a5G7r-zIsX_4MXL9E9lo2l5Cltoo3l5VXYAvy1tNvF1H4AgHIppw priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k2gICNxo1Y3dhLbJwSlq9IDvVC0N8vPUgFJ2Wwl-u-ZcZJdLY8eN7ZXdmbG_sbzZYaQ17USZQKni3Ffg4OimsRs4wKLVgWunXIzlwmyn5qj0-p4US_GC7d-pFVOe2LeqEPn8Y58n0uNud5UVb-9-MmwahRGV8cSGjfJLUxdhpQuuZDrOxaMYlWlHr-VmQm138N5hd-UccEAtwjN9NZ5lNP2_wtr_k2Z_CNumo-j-T1yd8SR9N0g-PvkRmwfkNtDZcmrh-TXIZgugtH2jE58q5YmvKsB2E2RUE5tG6jt_YYTQN257WmX6MHJl48fWKlhKD3p7Te7R4_hUIU_WHY_6BzcaFCsK8oBBNJVB23t9Js_Iqfzw88HR2wsssB8M5MrlmIDQkneOg-DQtKAtpuE4T4Zee3LEEJSdSxL6WoRHI9147QXScMzqSonHpOdtmvjU0IT7AYVuHcuNbyKulQp1QDIvA3CScChBSmnV238mIEcC2F8NzkSLpQZxGNAPCaLx-iCvFmPuRjyb1zb-z1KcN0Tc2fnB93yzIymaDyqEgfXHFZchTJqVzppvbPcK1hwKsjuJH8zGnRvNupXkFfrZjBFjK_YNnaXuQ_gQ-iiCvJkUJf1TITEVH7NrCBqS5G2prrd0p5_zem-kcfCYS8uyN6kc5t5_f9dPLt-Gc_JHY5mkHlIu2RntbyMLwBfrdzLbES_AXNUIII priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VIiQuiDeBgozEjUas7cSxj7B0VXqgF4p6s_wsFZCgzVai_56x86gWChLH2DOR45mxv8mMxwCvaslpRKerZK5GB0WKWBphfRmM9ExZaRc2J8h-FIcn1dFpfboDbDoLk5P2c0nLvExP2WFvetxo0mEwxksEHFyV6gbcTKXbk1YvxXL-r5IiVxVV4_mYBZfXsG7tQblU_3X48s80yd9ipXkLWt2FOyN2JG-H0d6DndDeh1vDbZKXD-DnAZprAqDtGZlyrFoS0_8ZhNokJZET03pieneVB0DsuelJF8ny-POH9yVVyEqOe_PV7JMj3EjxBevuO1mh64zKdEkYAj-y6bCvnZ7ZQzhZHXxaHpbjxQqlE4tmU8YgUBDRGeuQyUeFCFvEFOJrAqsd9d5HWQdKG1tzb1mohVWOR4VtjawsfwS7bdeGJ0AirgAVunQ2ClYFRWWMNYIwZzy3DWLPAug01dqNVcfT5RffdI5-c6kH8WgUj87i0aqA1zPPj6Hmxj-p3yUJzpSpXnZu6NZnetQf7Vij0OXmEr-48jQoS21jnDXMSfzgWMDeJH89GnGvEw96v7KqC3g5d6P5pZiKaUN3kWkQEyKJLODxoC7zSHiTyveJRQFyS5G2hrrd055_ySW-U-4Kw_W3gP1J567G9fe5ePp_5M_gNktmkXOR9mB3s74IzxFjbeyLbFS_AHt8Hkw priority: 102 providerName: Springer Nature |
| Title | Estimating infection fatality risk and ascertainment bias of COVID-19 in Osaka, Japan from February 2020 to January 2022 |
| URI | https://link.springer.com/article/10.1038/s41598-023-32639-9 https://www.ncbi.nlm.nih.gov/pubmed/37016060 https://www.proquest.com/docview/2795094845 https://www.proquest.com/docview/2796158458 https://pubmed.ncbi.nlm.nih.gov/PMC10072030 https://doaj.org/article/c27952338bc04d1e9b1b7acba2c85c1f |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_tQ0i8IL4JjMpIvLFA7XzYfkCoK61GJTYEFPUtsh17TIwE2k5a_3vOTtKpUHjgKartSx3fXe538fkO4HkmEurQ6YqZydBBEbmLVa7L2CpRMqmF7usQIHuSH0_TySyb7UBX7qhdwMVW187Xk5rOL15e_Vy9QYV_3RwZF68WaIT8QTGWxAhGEhnLXdhHy8S9or5v4X6T65vJlMr27Mx20g37FNL4b8Oef4ZQ_raPGszT-DbcanElGTSCcAd2bHUXbjSVJlf34GqEquzBaXVGuvirijj_7QZhOPEB5kRVJVELcx0jQPS5WpDakeHpl3dvYyqRlJwu1Dd1SCZoZPEG8_o7GaNbjYK2IgxBIVnW2Fd1v9l9mI5Hn4fHcVt0ITZ5ny9jZ3NkkjNKGyQqnUT0nTu__cctywwty9KJzFLKdZaUmtks19IkTmIbF6lOHsBeVVf2ERCHb4cU3T3tcpZaSYVzGQI0o8pEc8SlEdBuqQvTZiT3hTEuirAznoiiYU-B7CkCewoZwYs1zY8mH8c_Rx95Dq5H-lzaoaGenxWtahaGcYnueCLwidOSWqmp5spoxYzAB3YRHHT8Lzr5LDwNesYizSJ4tu5G1fT7Laqy9WUYg3gRh4gIHjbisp5Jwn1qv7wfgdgQpI2pbvZU519D-m8f18Lw3RzBYSdz1_P6-1o8_v9_egI3mVeRELN0AHvL-aV9ilhsqXuwy2e8B_uDweTTBK9Ho5MPH7F1mA974ftGL6jgL-SBNT8 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VrRC8IG4CBYwETzTqxs5hPyBE213ttmWLUIv6lvosFZCUZivYP8VvZJxjV8vRtz4mdiLbc_gbz3gG4GXCWeTQ6AqpTtBA4akLZapMaCU3VCiu-qoOkJ2ko8N45yg5WoFf3V0YH1bZ6cRaUZtS-zPyDZoJn-uNx8nbs--hrxrlvatdCY2GLXbt7AeabNWb8TbS9xWlw8HB1ihsqwqEOu1n09DZFEfhtFQaoZJxAuFl6rx_K7M00ZExxvHERlGmEmYUtUmqhGZO4LuMx4rhf6_BaszQlOnB6uZg8uHj_FTH-83iSLS3c_qMb1S4Q_pbbJSFiJSYCMXSDlgXCvgXuv07SPMPT229AQ5vw60WuZJ3DavdgRVb3IXrTS3L2T34OUBl4eFvcUK6CK-COH86hECf-BB2IgtDZKUXUQhEncqKlI5s7X8ab4eRwE_JfiW_yHWyg9s4_uC8_EaGaLgjK88IxbUk0xLbiu6Z3ofDKyHAA-gVZWEfAXGof2I0KJVLaWxFxJ1LEAJqaZjKEPkGEHVLnes257kvvfE1r33vjOcNeXIkT16TJxcBvJ5_c9Zk_Li096an4Lynz9ZdvyjPT_JW-HPtmZcyxnHGsYmsUJHKpFaSao4TdgGsdfTPWxVS5QuGD-DFvBmF33t0ZGHLi7oPIlLswgN42LDLfCQs88kD034AfImRloa63FKcfq4TjPvIGYraP4D1jucW4_r_Wjy-fBrP4cbo4P1evjee7D6Bm9SLRB0FtQa96fmFfYrobqqetSJF4Piqpfg3WIVf4Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYgL4k2ggJHgRKNd20lsHxCCblfdFrUcKOrN9bNUQFI2W8H-NX4d4zx2tTx66zGxE9meh7_xjGcQepELRgIYXSm1ORgoogipLoxLvRaOSiPM0DQBsvvFzmG2e5QfraFf_V2YGFbZ68RGUbvKxjPyAeUy5noTWT4IXVjEh9H4zdn3NFaQip7WvpxGyyJ7fv4DzLf69WQEtH5J6Xj749ZO2lUYSG0x5LM0-AJGFKw2FmCTCxKgZhGir4t7mlvinAsi94RwkzNnqM8LIy0LEt5xkRkG_72CrnKWkyhj_IgvzneiBy0jsrunM2RiUMNeGe-zUZYCZmIylSt7YVMy4F849-9wzT98ts1WOL6FbnYYFr9tme42WvPlHXStrWo5v4t-boPaiEC4PMF9rFeJQzwnAsiPYzA71qXDurbLeARsTnWNq4C3Dj5NRimR8Ck-qPUXvYl3YUOHH0yrb3gMJjww9RxTWEk8q6Ct7J_pPXR4Kct_H62XVekfIhxAE2VgWppQ0MxLIkLIAQxa7ZjhgIETRPqlVrbLfh6LcHxVjReeCdWSRwF5VEMeJRP0avHNWZv748Le7yIFFz1j3u7mRTU9UZ0aUDayMWVMwIwzR7w0xHBtjaZWwIRDgjZ6-qtOmdRqyfoJer5oBjUQfTu69NV50wewKXQRCXrQsstiJIzHNILFMEFihZFWhrraUp5-blKNxxgaCvtAgjZ7nluO6_9r8ejiaTxD10F21fvJ_t5jdINGiWjCoTbQ-mx67p8AzJuZp408YXR82QL8G-S2YrE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimating+infection+fatality+risk+and+ascertainment+bias+of+COVID-19+in+Osaka%2C+Japan+from+February+2020+to+January+2022&rft.jtitle=Scientific+reports&rft.au=Zhang%2C+Tong&rft.au=Nishiura%2C+Hiroshi&rft.date=2023-04-04&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=13&rft_id=info:doi/10.1038%2Fs41598-023-32639-9&rft.externalDocID=PMC10072030 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |